Core Viewpoint - The company, Changfeng Pharmaceutical, is set to launch its IPO from September 26 to October 2, 2025, with a focus on inhalation technology and drugs for respiratory diseases [1] Group 1: IPO Details - The company plans to globally offer 41.198 million H-shares, with 10% allocated for Hong Kong and 90% for international sales [1] - The offering price is set at HKD 14.75 per share, with trading expected to commence on October 8, 2025 [1] Group 2: Business Focus - The core business involves the research, development, production, and commercialization of inhalation technology and drugs, primarily targeting respiratory diseases [1] - The company has received approvals for six products from the National Medical Products Administration and the FDA, generating sales revenue from these products [1] Group 3: Fund Utilization - The estimated net proceeds from the fundraising are approximately HKD 525 million [1] - 40% of the net proceeds will be allocated to the research, clinical development, and commercialization of inhalation formulation candidates [1] - 20% will be used for preclinical research, 30% for production facilities, equipment procurement, and management system upgrades, and 10% for working capital and general corporate purposes [1]
长风药业招股 拟全球发售4119.8万股H股
Zheng Quan Shi Bao Wang·2025-09-26 00:47